Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Incyte Corp filings on SEC EDGAR ↗
Incyte Corporation has decided not to proceed with its planned Phase 3 MAESTRA-3 study of INCB123667 in combination with bevacizumab for ovarian cancer. The decision was based on internal portfolio prioritization rather than safety or efficacy concerns and is not expected to impact the company's financial guidance.
Incyte CMO & Head of Late-Stage Dev. Steven H. Stein Sells $28.4M of Stock
Steven H. Stein, CMO & Head of Late-Stage Dev., sold 240,193 shares of Incyte Corp at $116.06 to $119.66 a share (average $118.39) in 5 transactions, worth $28.4M in total on Nov 6, 2026. Shares held after the trade: 30,916 (-61.1%).
Incyte Principal Accounting Officer Thomas Tray Sells $72.6K of Stock
Thomas Tray, Principal Accounting Officer, sold 610 shares of Incyte Corp at $118.96 a share, worth $72.6K in total on Nov 3, 2026. Shares held after the trade: 21,126 (-2.8%).
Incyte Corporation reported total revenues of $4.5 billion for the nine months ended September 30, 2026, a significant increase from $3.6 billion in the prior year. However, the company recorded a net loss of $784.8 million for the third quarter of 2026, primarily driven by a substantial increase in research and development expenses to $1.79 billion.
Incyte reported third quarter 2026 total revenue of $1.56 billion, a 14% year-over-year increase driven by strong sales of Jakafi ($827M) and Opzelura ($255M). The company raised its full-year 2026 financial guidance for total net sales and key product portfolios. Results were impacted by a one-time $1.23 billion R&D expense related to the acquisition of Vega Therapeutics.
Term
Q3 2026
“Our third quarter was marked by strong commercial performance, meaningful pipeline progress and important regulatory achievements. Net sales growth was strong in both the U.S. and internationally, creating a durable core business beyond Jakafi.”
Incyte President, Global Head of R&D Pablo J. Cagnoni Sells $298K of Stock
Pablo J. Cagnoni, President, Global Head of R&D, sold 2,642 shares of Incyte Corp at $112.71 a share, worth $298K in total on Oct 15, 2026. Shares held after the trade: 183,200 (-1.4%).